By Caroline
Valetkevitch
NEW YORK (Reuters) - MSCI’s gauge of stocks across
the globe rose for a 10th straight session on Friday and hit another record
high as investors anticipated new fiscal aid from Washington to help the U.S.
economy recover, while benchmark U.S. Treasury yields rose to their highest
levels since March.
On Wall
Street, all three major indexes hit record closing highs, with energy,
financial and materials leading gains among S&P sectors as investors
snapped up cyclical and under-priced value stocks. All three indexes also
posted gains for the week.
The Cboe
Volatility Index, Wall Street’s fear gauge, ended below 20 for the first time
since February 2020, shortly before the coronavirus pandemic roiled U.S.
stocks.
“We’re
underestimating the lag effect of all the money in the system as more and more
vaccinations are delivered and as more of the country reopens” from business
shutdowns, said Thomas Hayes, chairman and managing member of hedge fund Great
Hill Capital LLC in New York.
“We are
continuing this rotation that would be consistent with the new business cycle,
and as (bond) yields go up, value and cyclicals will lead,” Hayes said.
U.S.
President Joe Biden pushed for the first major legislative achievement of his
term, turning to a bipartisan group of local officials for help on his $1.9
trillion coronavirus relief plan.
The dollar
was slightly higher, coming off its strongest level for the day, as risk
appetite returned to the market, while Bitcoin was down 1.3% on the day at
$47,356, after hitting a record high of $49,000. It posted gains of roughly 20%
in a milestone week marked by the endorsement of major firms such as Elon
Musk’s Tesla.
The Dow
Jones Industrial Average rose 27.7 points, or 0.09%, to 31,458.4, the S&P
500 gained 18.45 points, or 0.47%, to 3,934.83 and the Nasdaq Composite added
69.70 points, or 0.5%, to 14,095.47.
The U.S.
stock market will be closed on Monday because of the Presidents Day holiday.
More
https://www.reuters.com/article/global-markets/global-markets-stocks-hit-record-highs-yields-highest-since-march-idUSL1N2KI2GQ
Warren
Buffett’s favorite valuation metric is ringing an alarm
Last Updated: Feb 13, 2021, 09:10 AM
With U.S. equity indexes rising to fresh
records again this week, one of Warren Buffett’s most-famous catchphrases comes
to mind: Investors should “be fearful when others are greedy.”
Any Buffett disciple who checks in on the billionaire investor’s favorite
market valuation metric these days may get the urge to shriek in terror.
The “Buffett Indicator” is a simple
ratio: The total market capitalization of U.S. stocks divided by the total
dollar value of the nation’s gross domestic product. It first crossed above its
previous dot-com era peak in 2019. Still, it has been trending higher for
decades, and if there’s one mantra investors love even more than Buffett’s
it’s, “the trend is your friend.”
However, in recent weeks, even that
long-term trend fails to justify the metric’s frothy appearance. With U.S.
market cap more than double the level of estimated GDP for the current quarter,
the ratio has surged to the highest-ever reading above its long-term trend,
according to an analysis by the blog Current Market Valuation, suggesting a
“strongly overvalued” situation.
Of course, with the Federal Reserve
holding rates near zero and buying bonds for the foreseeable future, and an
abundance of savings and fiscal stimulus set to trigger blockbuster growth in
GDP and corporate earnings, it’s fair to wonder if this is yet another of the
many false alarms that have sounded during the past decade.
“It highlights the remarkable mania we
are witnessing in the U.S. equity market,” said Michael O’Rourke, chief market
strategist at JonesTrading. “Even if one expected those (Fed) policies to be
permanent, which they should not be, it still would not justify paying two
times the 25-year average for stocks.”
Read more at:
https://economictimes.indiatimes.com/markets/stocks/news/warren-buffetts-favorite-valuation-metric-is-ringing-an-alarm/articleshow/80891490.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Back
in the real economy, far from central bankster socialist handouts to
billionaires, things aren’t just a little gloomy, they are closer to jet black.
Police
emphasize clampdown on crowds as Mardi Gras nears
By
KEVIN McGILL
February 12, 2021
Crowds are usually welcome and even encouraged
in tourist-dependent New Orleans in the days leading up to Mardi Gras but as
the final weekend of the 2021 season began Friday, police warned that crowds
won’t be tolerated amid efforts to slow the spread of the coronavirus.
Police chief Shaun Ferguson held a news
conference with state police and the New Orleans sheriff to drive home the
point, saying a bar closure order that took effect Friday would be enforced
through Fat Tuesday, the end of the annual pre-Lenten festivities.
All parades in the city have been canceled.
Mardi Gras celebrations last year are now
believed to have contributed to an early surge of infections in Louisiana.
The city said Bourbon Street would be closed to
cars and pedestrians from 7 p.m. to 3 a.m. each day, with access limited to
residents, business employees, hotel guests and restaurant patrons. On Mardi
Gras itself, the closure will begin at 7 a.m., Ferguson said.
Restaurant capacity will be limited as it has
been throughout the pandemic. And bars, including those that have temporary
food permits enabling them to operate as restaurants, will be closed — not just
in the French Quarter but throughout the city — until Ash Wednesday.
Other popular entertainment areas, including
Decatur Street in the French Quarter and Frenchmen Street in the nearby Marigny
neighborhood were to be shut down during what are normally peak hours. And a
popular corridor outside the French Quarter that is a gathering spot for locals
was being put off limits with fencing.
Ferguson said police will be on the lookout
throughout the city for violators of the bar shutdown.
More
https://apnews.com/article/louisiana-coronavirus-pandemic-new-orleans-mardi-gras-fda74cf29143fe31c8b999d6358d69ef
2021 Looks
Like a Black Hole for Battered European Tourism
Paul Tugwell, Flavia
Rotondi and Alberto Brambilla February 12, 2021
(Bloomberg) -- Across Southern Europe’s tourist hotspots,
all they can do is get ready and hope.
Vaccinations for the coronavirus are being rolled out, but
it’s going to be months before enough shots are delivered that people can start crowding onto planes,
taking cruises, or hanging out in packed bars along the beach. That means
businesses are largely in the dark about this year’s summer season.
The expectation is that it will be better than 2020, but
that’s a low bar to hit. On the Greek island of Santorini, just three cruise
ships arrived last year, compared with close to 600 in 2019. European
Commission figures released on Thursday showed non-resident holiday
nights in Italy, Spain and Greece fell at least 70%, and it warned the industry
to brace for another quiet year.
“Tourism flows on the whole are not expected to fully
recover to their pre-crisis levels in 2021,” the commission said. In Italy,
tourism will lag behind the broader economic recovery as visitors “only
gradually return as uncertainty diminishes.”
For those in the industry, that’s already apparent
less than two months into the year. Paolo Manca, who runs the Felix Hotels
chain in Sardinia, says he would normally see summer reservations at 30% by now
as people grow weary of long winter nights. Instead, he’s looking at near empty
books.
Tourism is
crucial for many places along Southern Europe. It accounts for 21% of the
economy in Greece, and 17% in Portugal. It’s often the main employer in regions
where other industries are absent, providing crucial income for families and
support for local economies.
The outlook
will improve as vaccinations continue, with pent-up demand leading to more
spontaneous holiday bookings. But the emergence of vaccine-resistant strains
across the continent could scupper that.
Even if
there’s a surge in last-minute bookings, the benefits won’t be felt evenly. The
European Commission says they will favor destinations at home or within driving
distance over places like Greece and Portugal.
More
https://www.msn.com/en-us/travel/news/2021-looks-like-a-black-hole-for-battered-european-tourism/ar-BB1dCl1r
Another
Remote-Work Year Looms as Office-Reopening Plans Are Delayed
Return dates
get pushed to September or beyond, keeping firms and employees in ‘moment of
limbo’
Feb. 11, 2021 5:30 am ET
The hardest question to answer for American corporations:
When should offices reopen?
From Silicon Valley to Tennessee to Pennsylvania, high
hopes that a rapid vaccine rollout in early 2021 would send millions of workers
back into offices by spring have been scuttled. Many companies are pushing
workplace return dates to September—and beyond—or refusing to commit to
specific dates, telling employees it will be a wait-and-see remote-work year.
The delays span industries. Qurate Retail Inc., QRTEB -0.46% the parent company of brands such
as Ballard Designs, QVC and HSN, recently shifted its planned May return to
offices in the Philadelphia area, Atlanta and other cities until September at
the earliest. TechnologyAdvice, a marketing firm in Nashville, initially told
employees to plan on Feb. 1 as their return date. The company then pushed the
date back to August. Now, TA has decided it will begin a hybrid in-office
schedule in the fall of 2021, letting workers choose whether to work remotely
or come in, the company says.
Return-to-office dates have shifted so much in the past
year that some companies aren’t sharing them with employees. Shipping giant United Parcel Service Inc., UPS -0.75% based in Atlanta, and
financial-services firm Fidelity Investments Inc., based in Boston, haven’t
announced return dates, instead telling workers signing on from home that the
companies are monitoring the coronavirus pandemic and will call workers
back when it is safe.
Nearly a year of makeshift work at home has weighed on
employees, leaders say. While many companies say productivity is up, executives worry that creativity is suffering
and say that burnout is on the rise . Even so, bosses
struggle to say when things will change.
---- A new survey of 2,200 U.S. workers by the Conference
Board, a research group, found that 44% of employees polled didn’t know their
company’s plans to return to the workplace. That is up from last September,
when 37% of respondents polled by the group said they were unclear on their
back-to-the-office plan.
More
https://www.wsj.com/articles/another-remote-work-year-looms-as-office-reopening-plans-are-delayed-11613039402?mod=mhp
Finally,
everyone wants a handout. But why?
Is
there something fishy in US chips? Why should Uncle Sam be the Sole financier of
the Plaice? If they financed this
themselves, wouldn’t it be Brill? Surely, they’re flush enough for first Dabs
at finance. Uncle Sam should dig in his 'Eels, resist this ploy and flex his Mussels. US chip
makers should stop Pouting and get their Skates on and start building. Time for
a different US chip Tuna?
U.S. chip
industry calls on Biden administration to fund factories
February 11, 2021 10:26 AM
(Reuters) -
A group of U.S. chip companies on Thursday sent a letter to President Joe Biden
urging him to provide “substantial funding for incentives for semiconductor
manufacturing” as part of his economic recovery and infrastructure plans.
The chief
executives of major U.S. firms such as Intel Corp, Qualcomm Inc, Micron
Technology Inc and Advanced Micro Devices Inc signed onto the letter.
It comes as
a global chip shortage has idled factory lines at Ford Motor Co and General
Motors Co, with executives at the automakers predicting billions in lost
profit. Tight chip supplies have even made it hard for consumers to buy popular
gaming consoles such as Microsoft Corp’s Xbox and Sony Corp’s Playstation.
The missing
chips are mostly manufactured in countries such as Taiwan and Korea, which have
come to dominate the industry. The letter, sent by the Semiconductor Industry
Association, said that the U.S. share of semiconductor manufacturing dropped
from 37% in 1990 to 12% today.
“This is
largely because the governments of our global competitors offer significant
incentives and subsidies to attract new semiconductor manufacturing facilities,
while the U.S. does not,” the group said.
Congress
last year authorized subsidies for chip manufacturing and semiconductor
research, but lawmakers must still decide how much funding to provide. The U.S.
chip group urged Biden to provide such funding in the form of grants or tax
credits.
More
https://www.reuters.com/article/us-usa-semiconductors/u-s-chip-industry-calls-on-biden-administration-to-fund-factories-idUSKBN2AB11H
Covid-19 Corner
This
section will continue until it becomes unneeded.
One dose of
COVID-19 vaccine may be good for recovered patients
Feb. 12, 2021 / 3:05 AM
Could one
shot of a coronavirus vaccine be sufficient if you suffered a case of COVID-19
earlier in the pandemic?
Yes, new
research claims.
A pair of new, small studies found that patients previously
infected with COVID-19 who were given their first vaccine dose showed the sort
of robust immune response that people generally tend to have following their
second "booster" dose.
"People that have had COVID-19 before, they make
antibodies very quickly to much higher levels than those that had no experience
with the virus," said Dr. Viviana Simon, senior researcher on one of the
studies and a professor of microbiology and infectious diseases at the Icahn
School of Medicine at Mount Sinai in New York City.
RELATED CDC:
No need to quarantine during first 3 months after COVID-19 vaccination
"That led us to the conclusion that a second shot of
the vaccine should not be necessary in individuals that have been previously
infected," Simon said. "That would save vaccine doses and also would
limit the discomfort experienced by people upon vaccination."
However, these findings are likely a moot point given the
practical considerations of the pandemic, other experts said.
The new papers, published this week on the preprint server
medRxiv, need to be peer-reviewed and verified by follow-up research before a
single-shot strategy could be implemented in previously infected people, and
that will take precious time.
Future studies examining whether a single vaccine dose
would be sufficient in any group of people "would take several months to
get a meaningful answer," said Dr. Anthony Fauci, director of the U.S.
National Institute of Allergy and Infectious Diseases.
More
https://www.upi.com/Health_News/2021/02/12/One-dose-of-COVID-19-vaccine-may-be-good-for-recovered-patients/4321613086490/
India,
pharmacy of the world, falls behind on vaccinations at home
February 12, 2021 9:52 AM
By Neha
Arora , Krishna
N. Das
NEW
DELHI (Reuters) - India has won plaudits for gifting and selling COVID-19
vaccines around the world, but it will have to crank up the pace of
immunisations at home to meet its targets.
Having
reported the world’s second-highest number of COVID-19 cases after the United
States, India wants to innoculate 300 million people - a fifth of its
population - against the virus by August.
However, in
four weeks health workers vaccinated only 7.5 million frontline workers on
priority, a rate at which it would take India several years to reach its goal.
“Vaccination
programmes usually start off slow and then ramp up as logistic and operational
issues are sorted out,” said Gagandeep Kang, Professor of Microbiology at the
Christian Medical College in Vellore.
“In India,
we are fortunate that supply of vaccines is not a rate-limiting step, but to
meet the timelines set by the government, we will have to immunise somewhere
between 4 and 5 times more people each day than we are doing today.”
The
government says it is ready to step up vaccinations from next month, including
by roping in more private hospitals, once identified groups from the general
public are given the shots. A government online vaccine platform told Reuters
it could handle 10 million inoculations a day.
The health
ministry also says India is the fastest to reach the 7 million milestone,
though immunisation relative to population has been much higher in many other
countries.
Several big
Indian states, such as Tamil Nadu and Punjab, have covered fewer than 40% of
their high-risk people such as nurses, doctors and hospital cleaning staff,
worrying the federal government.
More
https://www.reuters.com/article/us-health-coronavirus-india-vaccine/india-pharmacy-of-the-world-falls-behind-on-vaccinations-at-home-idUSKBN2AC0TI?il=0
As Covid
Evolves, Treatments May Prove as Important as Vaccines
The FDA has
approved only a few therapeutic drugs. Many studies suggest promising options.
Feb. 11, 2021 5:47 pm ET
New Covid-19 variants are eluding antibody treatments and
may render vaccines less effective. To keep up, physicians need a broader
arsenal of therapies that the virus can’t easily defeat. But the Food and Drug
Administration has authorized precious few treatments for Covid-19, namely
Gilead’s antiviral remdesivir and monoclonal antibodies by Regeneron Pharmaceuticals and Eli Lilly . The National Institutes of Health
has prioritized monoclonal antibodies —essentially
manufactured copies of human antibodies—which have shown promise against other
diseases, including cancer.
The rub is that mutations that alter the shape of the spike
protein on the surface of the virus—as variants from the U.K., Brazil and South
Africa do—can deform the sites to which antibodies bind before they neutralize
the virus. Developing new antibody cocktails that target new variants could
become a game of Whac-A-Mole.
The good news is that Gilead says remdesivir appears effective against the new
strains. It is the only FDA-approved antiviral for Covid-19, and the five-day
infusion treatment is limited to hospital patients. Antivirals, which stop
viruses from replicating in human cells, are typically most effective early in
an illness. So finding other effective antivirals, especially ones that can be
prescribed to outpatients, should be a priority.
----Merck is testing an oral compound, molnupiravir, that works by creating errors in the virus’s copying code .
One advantage to that approach is that viruses don’t appear to develop
resistance. Merck hopes to share early efficacy results from a late-stage trial
by March.
The antidepressant fluvoxamine has also shown promise as an
antiviral and anti-inflammatory. A small randomized control trial published in
the Journal of the American Medical Association in
November found that not one patient who received fluvoxamine within seven days
of symptom onset experienced clinical deterioration versus 8.3% of those who
received a placebo. Another small non-randomized trial of infected horse
racetrack workers in California a found that none who took the drug got sicker,
whereas 12.5% of those who didn’t were hospitalized. A larger clinical trial is
needed to support the antiviral benefit, but the drug certainly deserves
further study.
More
https://www.wsj.com/articles/as-covid-evolves-treatments-may-prove-as-important-as-vaccines-11613083638?mod=opinion_lead_pos6
Next, some very useful vaccine
links kindly sent along from a LIR reader in Canada. The links come from a most
informative update from Stanford Hospital in California.
World Health Organization - Landscape
of COVID-19 candidate vaccines . https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
NY Times Coronavirus Vaccine
Tracker . https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
Stanford Website . https://racetoacure.stanford.edu/clinical-trials/132
FDA information . https://www.fda.gov/media/139638/download
Regulatory Focus COVID-19
vaccine tracker . https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
Some more useful Covid links.
Johns Hopkins Coronavirus
resource centre
https://coronavirus.jhu.edu/map.html
Rt Covid-19
https://rt.live/
Covid19info.live
https://wuflu.live/
The Spectator
Covid-19 data tracker (UK)
https://data.spectator.co.uk/city/national
Technology Update.
With events happening fast in the development of solar power and
graphene, I’ve added this section. Updates as they get reported. Is converting
sunlight to usable cheap AC or DC energy mankind’s future from the 21st
century onwards.
London to
trial hydrogen electric rapid response ambulance prototype
By Paul
Ridden
February 10, 2021
Hydrogen commercial vehicle conversion
company ULEMCo and industry partners have agreed the design of a new fuel cell
rapid response ambulance prototype that's destined to hit the streets of London
later this year.
The vehicle is dubbed the ZERRO ambulance,
which stands for Zero Emission Rapid Response Operations, and is being funded
by the UK's Office for Zero Emission Vehicles – a cross government group
working to support the transition to zero (local) emission vehicles.
The electric drive prototype will feature a 92-kWh battery
pack and a hydrogen fuel cell range extender comprising a 30-kW fuel cell from
Ballard and 8 kg of H2 storage on board. The ambulance is being designed for a
top speed of 90 mph (145 km/h) and a targeted average daily range of 200 miles
(320 km).
The drivetrain, chassis and bespoke body of the vehicle are
being manufactured by Woodall Nicholson Group’s Mellor, Promech Technologies
and VCS Limited. VCS has experience in the field, last year producing the UK's
first all-electric ambulance in the shape of the Electric Dual Crewed Ambulance that began trials in the
West Midlands on October. While Promech will leverage its existing battery
technology and expertise. Other project partners Ocado and Lyra Electronics
bring the former's practical experience in using electric vehicles and the
latter's specialist DC-DC electronics capabilities to the design.
The new
ZERRO vehicle will have the ability to haul a payload of at least 900 kg and
benefit from a low access floor to negate the need for patient lifting
equipment to be included.
"The
aim of the project is to show that this weight target can be met with the
combination of this powertrain configuration and the lightweight structure, and
using a low floor design rather than needing to include heavy lifting
equipment, alongside work to integrate the internal electrical power needs
within overall vehicle electrical system design," said ULEMCo.
After a year
spent working on the design phase of the project, ULEMCo and partners now plan
to build and deliver the fully approved working prototype to the London
Ambulance Service NHS Trust by the (northern) fall of 2021.
https://newatlas.com/automotive/zerro-hydrogen-electric-rapid-response-ambulance-prototype/
Planned
Hydrogen Projects Outnumber Current Projects across Europe as Demand for Clean
Energy Increases
Written by AZoCleantech Feb 10 2021
The number
of planned or announced hydrogen projects across Europe is almost double that
of current operational projects as demand for clean energy solutions heightens
globally, according to research by global law firm DLA Piper and inspiratia.
DLA Piper’s
report The
Hydrogen Revolution in EMEA shows that there are 192 planned or announced hydrogen
projects in Europe compared to 107 current operational projects on the
continent. The report analyses how the hydrogen market is developing, and the
different approaches that are being taken across Europe, the Middle East and
North Africa.
When burned,
hydrogen only leaves water as a by-product, making it an attractive
emission-free alternative to traditional energy sources. Its potential is
further demonstrated by the fact it is an energy carrier with an energy density
more than twice that of natural gas. Those characteristics cause clean hydrogen
to have the potential to be a key component of the drive towards a net zero
future. DLA Piper’s report argues that investment in clean energy, such as
hydrogen, will be a vital part of global economic recovery post pandemic and
building a sustainable future.
---- Current forecasts anticipate that
demand for hydrogen will continue to steadily increase towards 2050. Data
suggest that global hydrogen demand will require additional generation of
35-1,100TWh per year by 2030, increasing to 300-19,000TWh per year by 2050.
However, the challenge for hydrogen, according to DLA Piper, is to unlock
pathways to the production of blue and, in particular, green hydrogen, and to
serve increasing demand with decreased reliance on those methods of production
which do not serve the zero-carbon agenda. The report sheds light on the
different approaches to that which are being taken around the world.
More
https://www.azocleantech.com/news.aspx?newsID=28835
Finally, who invented the light bulb? And
it mostly wasn’t Edison. He lost his patent suit and joined forces with
Englishman Joseph Swan. But it’s more complicated than that. Who didn’t invent
the light bulb?
Who Invented
the Light Bulb?
By Elizabeth
Palermo - Staff Writer August 17, 2017
Though Thomas Edison is usually credited with the invention
of the light bulb, the famous American inventor wasn't the only one who
contributed to the development of this revolutionary technology. Many other
notable figures are also remembered for their work with electric batteries,
lamps and the creation of the first incandescent bulbs.
Early
research & developments
The story of the light bulb begins long before Edison
patented the first commercially successful bulb in 1879. In 1800, Italian
inventor Alessandro Volta developed the first practical method of generating
electricity, the voltaic pile. Made of alternating discs of zinc and copper —
interspersed with layers of cardboards soaked in salt water — the pile
conducted electricity when a copper wire was connected at either end. While
actually a predecessor of the
modern battery , Volta's glowing copper wire is also considered to be one of
the earliest manifestations of incandescent lighting.
Not long after Volta presented his discovery of a
continuous source of electricity to the Royal Society in London, Humphry Davy,
an English chemist and inventor, produced the world's first electric lamp by
connecting voltaic piles to charcoal electrodes. Davy's 1802 invention was
known as an electric arc lamp, named for the bright arc of light emitted
between its two carbon rods.
----Joseph
Swan vs. Thomas Edison
In 1850, English chemist Joseph Swan tackled the
cost-effectiveness problem of previous inventors and by 1860 he had developed a
light bulb that used carbonized paper filaments in place of ones made of
platinum. Swan received a patent in the United Kingdom in 1878, and in February
1879 he demonstrated
a working lamp in a lecture in Newcastle, England, according to the
Smithsonian Institution. Like earlier renditions of the light bulb, Swan's
filaments were placed in a vacuum tube to minimize their exposure to oxygen ,
extending their lifespan. Unfortunately for Swan, the vacuum pumps of his day
were not efficient as they are now, and while his prototype worked well for a
demonstration, it was impractical in actual use.
Edison realized that the problem with Swan's design was the
filament. A thin filament with high electrical resistance would make a lamp
practical because it would require only a little current to make it glow. He
demonstrated his light bulb in December 1879. Swan incorporated the improvement
into his light bulbs and founded an electrical lighting company in England.
Edison sued for patent infringement, but Swan's patent was a strong claim, at
least in the United Kingdom, and the two inventors eventually joined forces and
formed Edison-Swan United, which became one of the world’s largest manufacturers of
light bulbs , according to the Museum of Unnatural Mystery.
---- The success of Edison's light bulb was followed by the founding of the
Edison Electric Illuminating Company of New York in 1880. The company was
started with financial contributions from J.P. Morgan and other wealthy
investors of the time. The company constructed the first electrical generating
stations that would power electrical system and newly patented bulbs. The first
generating station was opened in September 1882 on Pearl Street in lower Manhattan.
Other
inventors, such as William Sawyer and Albon Man, threw in the towel, merging
their company with Edison's to form General Electric, according to the U.S.
Department of Energy (DOE).
More
https://www.livescience.com/43424-who-invented-the-light-bulb.html
This weekend’s musical diversion. The right and wrong way to play Vivaldi RV
558. Up first the right way. The first movement for comparison. (About 5
minutes.)
Vivaldi Molti
Istromenti Concerto RV 558
https://www.youtube.com/watch?v=Y_j426zXI0Q&feature=related
Next the wrong way. Maybe it wasn’t a
good idea to share that bottle of Johnnie Walker Blue Label right before the
performance! (About 6+ minutes if you can stand it.)
Vivaldi -
Concerto C Major RV 558 - 1. Allegro Molto
https://www.youtube.com/watch?v=9TspehIRbOQ
Johnnie
Walker Blue Label - Ghost & Rare Port Ellen
(70cl, 43.8%)
https://www.masterofmalt.com/whiskies/johnnie-walker/johnnie-walker-blue-label-ghost-and-rare-port-ellen-whisky/?gclid=Cj0KCQiAyJOBBhDCARIsAJG2h5eJuSTnheelkOPFi81Ny74nUljuVxhAvTG1vn6AHb35jgGq9kEcSkwaApQ2EALw_wcB
Next, this week’s chess masterclass. (About 7 minutes.)
He Was Big
And Strong... || Dubov vs Carlsen || Opera (2021)
https://www.youtube.com/watch?v=iiPwO79yYbs
It is better to keep your mouth closed and let people think you
are a fool than to open it and remove all doubt.
Mark Twain
No comments:
Post a Comment